Unknown

Dataset Information

0

Ficolin-2 Plasma Level Assesses Liver Fibrosis in Non-Alcoholic Fatty Liver Disease.


ABSTRACT: Fibrosis is the strongest predictor for disease-specific mortality in non-alcoholic fatty liver diseases (NAFLD), but the need for liver biopsy limits its diagnosis. We assessed the performance of plasma ficolin-2 (FCN-2) as a biomarker of fibrosis identified by an in silico discovery strategy. Two hundred and thirty-five morbidly obese (MO) subjects with biopsy-proven NAFLD stratified by fibrosis stage (F0, n = 44; F1, n = 134; F2, n = 46; F3/F4, n = 11) and 40 cirrhotic patients were enrolled. The cohort was subdivided into discovery (n = 76) and validation groups (n = 159). The plasma level of FCN-2 and other candidate markers was determined. FCN-2 was inversely correlated with the stage of liver fibrosis (ρ = −0.49, p < 0.001) independently of steatosis (p = 0.90), inflammation (p = 0.57), and ballooning (p = 0.59). In the global cohort, FCN-2 level decreased significantly in a stepwise fashion from F0/F1 (median 4753 ng/mL) to F2−F3−F4 (2760 ng/mL) and in cirrhotic subjects (1418 ng/mL). The diagnostic performance of FCN-2 in detecting F ≥ 2 was higher than other indexes (APRI, FIB-4) (AUROC 0.82, 0.68, and 0.6, respectively). The accuracy improved when combined with APRI score and HDL values (FCNscore, AUROC 0.85). Overall, the FCN-2 plasma level can accurately discriminate liver fibrosis status (minimal vs. moderate/advanced) significantly improving the fibrosis diagnostic algorithms.

SUBMITTER: Giraudi PJ 

PROVIDER: S-EPMC8911336 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Ficolin-2 Plasma Level Assesses Liver Fibrosis in Non-Alcoholic Fatty Liver Disease.

Giraudi Pablo J PJ   Salvoza Noel N   Bonazza Deborah D   Saitta Carlo C   Lombardo Daniele D   Casagranda Biagio B   de Manzini Nicolò N   Pollicino Teresa T   Raimondo Giovanni G   Tiribelli Claudio C   Palmisano Silvia S   Rosso Natalia N  

International journal of molecular sciences 20220304 5


Fibrosis is the strongest predictor for disease-specific mortality in non-alcoholic fatty liver diseases (NAFLD), but the need for liver biopsy limits its diagnosis. We assessed the performance of plasma ficolin-2 (FCN-2) as a biomarker of fibrosis identified by an in silico discovery strategy. Two hundred and thirty-five morbidly obese (MO) subjects with biopsy-proven NAFLD stratified by fibrosis stage (F0, n = 44; F1, n = 134; F2, n = 46; F3/F4, n = 11) and 40 cirrhotic patients were enrolled.  ...[more]

Similar Datasets

| S-EPMC7725521 | biostudies-literature
| S-EPMC6783644 | biostudies-literature
| S-EPMC5031527 | biostudies-literature
| S-EPMC1860097 | biostudies-literature
| S-SCDT-EMM-2018-10124 | biostudies-other
| S-EPMC8106094 | biostudies-literature
| S-EPMC6267957 | biostudies-literature
| S-EPMC7584064 | biostudies-literature
| S-EPMC6334080 | biostudies-literature
| S-EPMC6758911 | biostudies-literature